Chapter 1. Executive Summary
Chapter 2. Scope of The Study
2.1. Market Definition
2.2. Scope of The Study
2.2.1. Objectives of Report
Chapter 3. Evolve BI Methodology
Chapter 4. Market Insights and Trends
4.1. Supply/ Value Chain Analysis
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Threat of Substitutes
4.2.5. Industry Rivalry
4.3. Impact of COVID-19 on Remdesivir (COVID 19) Market
4.3.1. Impact on Market Size
4.3.2. End User Trend, Preferences and Budget Impact
4.3.3. Regulatory Framework/Government Policies
4.3.4. Key Players Strategy to Tackle Negative Impact
4.3.5. Opportunity Window
Chapter 5. Market Dynamics
5.1. Introduction
5.2. DRO Analysis
5.2.1. Drivers
5.2.2. Restraints
5.2.3. Opportunities
Chapter 6. Global Remdesivir (COVID 19) Market, By Dosage Type
6.1. Introduction
6.2. 5mg
6.3. 10 mg
6.4. 100mg
Chapter 7. Global Remdesivir (COVID 19) Market, By Distribution Channel
7.1. Introduction
7.2. Hospitals
7.3. Drug stores
7.4. Others
Chapter 8. Global Remdesivir (COVID 19) Market, By Region
8.1. Introduction
8.2. North America
8.2.1. Introduction
8.2.2. Driving Factors, Opportunity Analyzed and Key Trends
8.2.3. Market Size and Forecast, By Country, 2020 - 2028
8.2.4. Market Size and Forecast, By Dosage Type, 2020 - 2028
8.2.5. Market Size and Forecast, By Distribution Channel, 2020 – 2026
8.2.6. US
8.2.6.1. Introduction
8.2.6.2. Driving Factors, Opportunity Analyzed and Key Trends
8.2.6.3. Market Size and Forecast, By Dosage Type, 2020 - 2028
8.2.6.4. Market Size and Forecast, By Distribution Channel, 2020 - 2028
8.2.7. Canada
8.2.7.1. Introduction
8.2.7.2. Driving Factors, Opportunity Analyzed and Key Trends
8.2.7.3. Market Size and Forecast, By Dosage Type, 2020 - 2028
8.2.7.4. Market Size and Forecast, By Distribution Channel, 2020 - 2028
8.3. Europe
8.3.1. Introduction
8.3.2. Driving Factors, Opportunity Analyzed and Key Trends
8.3.3. Market Size and Forecast, By Country, 2020 - 2028
8.3.4. Market Size and Forecast, By Dosage Type, 2020 - 2028
8.3.5. Market Size and Forecast, By Distribution Channel, 2020 – 2026
8.3.6. Germany
8.3.6.1. Introduction
8.3.6.2. Driving Factors, Opportunity Analyzed and Key Trends
8.3.6.3. Market Size and Forecast, By Dosage Type, 2020 - 2028
8.3.6.4. Market Size and Forecast, By Distribution Channel, 2020 - 2028
8.3.7. France
8.3.7.1. Introduction
8.3.7.2. Driving Factors, Opportunity Analyzed and Key Trends
8.3.7.3. Market Size and Forecast, By Dosage Type, 2020 - 2028
8.3.7.4. Market Size and Forecast, By Distribution Channel, 2020 - 2028
8.3.8. UK
8.3.8.1. Introduction
8.3.8.2. Driving Factors, Opportunity Analyzed and Key Trends
8.3.8.3. Market Size and Forecast, By Dosage Type, 2020 - 2028
8.3.8.4. Market Size and Forecast, By Distribution Channel, 2020 - 2028
8.3.9. Italy
8.3.9.1. Introduction
8.3.9.2. Driving Factors, Opportunity Analyzed and Key Trends
8.3.9.3. Market Size and Forecast, By Dosage Type, 2020 - 2028
8.3.9.4. Market Size and Forecast, By Distribution Channel, 2020 - 2028
8.3.10. Rest of Europe
8.3.10.1. Introduction
8.3.10.2. Driving Factors, Opportunity Analyzed and Key Trends
8.3.10.3. Market Size and Forecast, By Dosage Type, 2020 - 2028
8.3.10.4. Market Size and Forecast, By Distribution Channel, 2020 - 2028
8.4. Asia-Pacific
8.4.1. Introduction
8.4.2. Driving Factors, Opportunity Analyzed and Key Trends
8.4.3. Market Size and Forecast, By Country, 2020 - 2028
8.4.4. Market Size and Forecast, By Dosage Type, 2020 - 2028
8.4.5. Market Size and Forecast, By Distribution Channel, 2020 - 2028
8.4.6. China
8.4.6.1. Introduction
8.4.6.2. Driving Factors, Opportunity Analyzed and Key Trends
8.4.6.3. Market Size and Forecast, By Dosage Type, 2020 - 2028
8.4.6.4. Market Size and Forecast, By Distribution Channel, 2020 - 2028
8.4.7. India
8.4.7.1. Introduction
8.4.7.2. Driving Factors, Opportunity Analyzed and Key Trends
8.4.7.3. Market Size and Forecast, By Dosage Type, 2020 - 2028
8.4.7.4. Market Size and Forecast, By Distribution Channel, 2020 - 2028
8.4.8. Japan
8.4.8.1. Introduction
8.4.8.2. Driving Factors, Opportunity Analyzed and Key Trends
8.4.8.3. Market Size and Forecast, By Dosage Type, 2020 - 2028
8.4.8.4. Market Size and Forecast, By Distribution Channel, 2020 - 2028
8.4.9. South Korea
8.4.9.1. Introduction
8.4.9.2. Driving Factors, Opportunity Analyzed and Key Trends
8.4.9.3. Market Size and Forecast, By Dosage Type, 2020 - 2028
8.4.9.4. Market Size and Forecast, By Distribution Channel, 2020 - 2028
8.4.10. Rest of Asia-Pacific
8.4.10.1. Introduction
8.4.10.2. Driving Factors, Opportunity Analyzed and Key Trends
8.4.10.3. Market Size and Forecast, By Dosage Type, 2020 - 2028
8.4.10.4. Market Size and Forecast, By Distribution Channel, 2020 - 2028
8.5. Rest of The World (RoW)
8.5.1. Introduction
8.5.2. Driving Factors, Opportunity Analyzed and Key Trends
8.5.3. Market Size and Forecast, By Dosage Type, 2020 - 2028
8.5.4. Market Size and Forecast, By Distribution Channel, 2020 - 2028
8.5.5. Market Size and Forecast, By Region, 2020 - 2028
8.5.6. South America
8.5.6.1. Introduction
8.5.6.2. Driving Factors, Opportunity Analyzed and Key Trends
8.5.6.3. Market Size and Forecast, By Dosage Type, 2020 - 2028
8.5.6.4. Market Size and Forecast, By Distribution Channel, 2020 - 2028
8.5.7. Middle East and Africa
8.5.7.1. Introduction
8.5.7.2. Driving Factors, Opportunity Analyzed and Key Trends
8.5.7.3. Market Size and Forecast, By Dosage Type, 2020 - 2028
8.5.7.4. Market Size and Forecast, By Distribution Channel, 2020 - 2028
Chapter 9. Competitive Landscape
9.1. Introduction
9.2. Vendor Share Analysis, 2020/Key Players Positioning, 2020
Chapter 10. Company Profiles
10.1. Gilead Sciences, Inc.
10.1.1. Business Overview
10.1.2. Financial Analysis
10.1.3. Dosage Portfolio
10.1.4. Recent Development and Strategies Adopted
10.1.5. SWOT Analysis
10.2. Mylan
10.2.1. Business Overview
10.2.2. Financial Analysis
10.2.3. Dosage Portfolio
10.2.4. Recent Development and Strategies Adopted
10.2.5. SWOT Analysis
10.3. Cipla
10.3.1. Business Overview
10.3.2. Financial Analysis
10.3.3. Dosage Portfolio
10.3.4. Recent Development and Strategies Adopted
10.3.5. SWOT Analysis
10.4. Hetero Labs
10.4.1. Business Overview
10.4.2. Financial Analysis
10.4.3. Dosage Portfolio
10.4.4. Recent Development and Strategies Adopted
10.4.5. SWOT Analysis
10.5. Bright Gene
10.5.1. Business Overview
10.5.2. Financial Analysis
10.5.3. Dosage Portfolio
10.5.4. Recent Development and Strategies Adopted
10.5.5. SWOT Analysis
10.6. Hainan Haiyao
10.6.1. Business Overview
10.6.2. Financial Analysis
10.6.3. Dosage Portfolio
10.6.4. Recent Development and Strategies Adopted
10.6.5. SWOT Analysis
10.7. Kelun Pharma
10.7.1. Business Overview
10.7.2. Financial Analysis
10.7.3. Dosage Portfolio
10.7.4. Recent Development and Strategies Adopted
10.7.5. SWOT Analysis
10.8. Hunan Warrant Pharmaceutical
10.8.1. Business Overview
10.8.2. Financial Analysis
10.8.3. Dosage Portfolio
10.8.4. Recent Development and Strategies Adopted
10.8.5. SWOT Analysis
10.9. Borui Bio-Pharmaceutical
10.9.1. Business Overview
10.9.2. Financial Analysis
10.9.3. Dosage Portfolio
10.9.4. Recent Development and Strategies Adopted
10.9.5. SWOT Analysis
10.10. Jubilant Life Sciences
10.10.1. Business Overview
10.10.2. Financial Analysis
10.10.3. Dosage Portfolio
10.10.4. Recent Development and Strategies Adopted
10.10.5. SWOT Analysis
Chapter 11. Key Takeaways